JNJ - Johnson & Johnson

NYSE - NYSE Delayed Price. Currency in USD
134.47
+1.99 (+1.50%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close132.48
Open132.45
Bid0.00 x 900
Ask0.00 x 1000
Day's Range132.19 - 135.00
52 Week Range118.62 - 148.32
Volume6,701,056
Avg. Volume6,504,630
Market Cap360.751B
Beta0.60
PE Ratio (TTM)267.34
EPS (TTM)0.50
Earnings DateOct 16, 2018
Forward Dividend & Yield3.60 (2.74%)
Ex-Dividend Date2018-08-27
1y Target Est143.35
Trade prices are not sourced from all markets
  • Investopedia2 days ago

    The Top UPS Shareholders (UPS)

    Learn about the history of United Parcel Service Inc., and the shipping company's top institutional and insider shareholders.

  • What Does Baxter International’s Valuation Trend Indicate?
    Market Realist2 days ago

    What Does Baxter International’s Valuation Trend Indicate?

    In 2012, Baxter International (BAX) adopted a $2 billion share buyback program. In November 2016 and February 2018, the company increased the program by $1.5 billion each.

  • A Closer Look at Allergan’s Business Segments in Q2 2018
    Market Realist2 days ago

    A Closer Look at Allergan’s Business Segments in Q2 2018

    As we discussed earlier, Allergan (AGN) has restructured its business over the last few years, and it now reports its revenues in three business segments.

  • 4 Mega-Cap Stocks to Buy As They’re Thrust Into the Spotlight
    InvestorPlace2 days ago

    4 Mega-Cap Stocks to Buy As They’re Thrust Into the Spotlight

    U.S. equities soared on Thursday, reversing a two-week malaise, after Walmart (NYSE:WMT) reported solid results and headlines that China’s Vice Commerce Minister would visit the United States for trade talks in late August. Analysts are looking for earnings of $1.15-per-share on revenues of $10.9 billion.

  • Pharma Stock Roundup: Blow for Bayer, FDA Nod for MRK Cancer Drug in New Indication
    Zacks2 days ago

    Pharma Stock Roundup: Blow for Bayer, FDA Nod for MRK Cancer Drug in New Indication

    Bayer's (BAYRY) Monsanto subsidiary faces $289 million fine in Roundup lawsuit. Merck/Eisai's drug Lenvima gets FDA approval to treat the most common form of liver cancer.

  • A Look at Allergan’s Valuation on August 16
    Market Realist2 days ago

    A Look at Allergan’s Valuation on August 16

    Allergan (AGN) is a leading specialty pharmaceutical company focused on developing, manufacturing, and commercializing pharmaceutical and biological products.

  • See what the IHS Markit Score report has to say about Johnson & Johnson.
    Markit2 days ago

    See what the IHS Markit Score report has to say about Johnson & Johnson.

    Johnson & Johnson NYSE:JNJ

  • Glaxo, J&J's Dual Drug HIV Regimen Succeeds in Phase III Study
    Zacks2 days ago

    Glaxo, J&J's Dual Drug HIV Regimen Succeeds in Phase III Study

    Glaxo (GSK) and Johnson and Johnson report positive top line results from a late-stage study of their injectable two-drug regimen for the treatment of HIV.

  • HBJ health care panel talks tech innovation, high patient costs
    American City Business Journals3 days ago

    HBJ health care panel talks tech innovation, high patient costs

    Houston Business Journal hosted its “Future of Health Care Panel” on Aug. 10 at the Junior League of Houston to chat with industry leaders about notable trends in health care they see and experience every day.

  • Reuters3 days ago

    Trump administration proposes production quota cuts for six opioids

    WASHINGTON/NEW YORK, Aug 16 (Reuters) - The Trump administration on Thursday proposed that U.S. drugmakers cut production quotas of the six most abused opioids by 10 percent next year to fight a nationwide addiction crisis. In a statement, the U.S. Justice Department and Drug Enforcement Administration (DEA) said the proposed cut would be in keeping with President Donald Trump's effort to cut opioid prescription fills by one-third within three years. Trump on Thursday also pressed U.S. Attorney General Jeff Sessions to sue drug manufacturers over the opioid crisis.

  • A Look at the Performance of Bausch Health’s Ortho Dermatologics
    Market Realist3 days ago

    A Look at the Performance of Bausch Health’s Ortho Dermatologics

    Bausch Health Companies’ (BHC) wholly-owned subsidiary Ortho Dermatologics generated revenue of $142.0 million in the second quarter compared to $162 million in the second quarter of 2017, reflecting a ~12% YoY (year-over-year) fall.

  • Why Is Johnson & Johnson (JNJ) Up 1% Since Its Last Earnings Report?
    Zacks3 days ago

    Why Is Johnson & Johnson (JNJ) Up 1% Since Its Last Earnings Report?

    Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Better Speculative Biotech Stock: Amarin Corporation vs. Geron Corporation
    Motley Fool3 days ago

    Better Speculative Biotech Stock: Amarin Corporation vs. Geron Corporation

    Amarin and Geron are both racing toward major binary events that could pay off for early shareholders in a big way.

  • Most Analysts Are Optimistic about Vertex Pharmaceuticals
    Market Realist3 days ago

    Most Analysts Are Optimistic about Vertex Pharmaceuticals

    How Is Vertex Pharmaceuticals Positioned in August? On February 12, the FDA approved Vertex Pharmaceuticals’ (VRTX) Symdeko, which is the company’s third cystic fibrosis drug in the US market. Symdeko continues to witness a strong launch in the US market, and demand has risen across the entire range of eligible patients.

  • Should Gilead Be Worried About This New Monthly HIV Medication?
    Motley Fool3 days ago

    Should Gilead Be Worried About This New Monthly HIV Medication?

    The devil is in the undisclosed details.

  • A Performance Overview of Bausch + Lomb
    Market Realist4 days ago

    A Performance Overview of Bausch + Lomb

    Bausch + Lomb, an international subsidiary of Bausch Health Companies (BHC), generated revenue of $1.21 billion in the second quarter compared to $1.22 billion in the second quarter of 2017, reflecting a ~1% YoY (year-over-year) fall. However, Bausch + Lomb witnessed ~4% YoY organic growth in the second quarter.

  • A Rare Genetic Aversion to Sweets Could Be Key to Fighting Obesity
    Bloomberg4 days ago

    A Rare Genetic Aversion to Sweets Could Be Key to Fighting Obesity

    People who have a rare genetic mutation called essential fructosuria lack the primary enzyme needed to metabolize fructose, a natural sugar found in honey, fruits and vegetables. No ill consequences have been linked to the defect, save for an aversion to sweets, and it appears to have a significant benefit: Those who have it seem to be at little risk of obesity, type 2 diabetes or serious liver ailments. “When I started contacting people who were taking care of these patients, there was literally no one — I couldn’t find anyone — who was fat or had type 2 diabetes,” said Richard Johnson, a pioneering metabolic-disease scientist at the University of Denver.

  • SurveyMonkey adds Emory dean to board of directors, balancing its gender representation
    American City Business Journals5 days ago

    SurveyMonkey adds Emory dean to board of directors, balancing its gender representation

    Erika Hayes James became the first African-American woman appointed dean of a top-25 business school when she was tapped for the role at the John H. Harland Dean of Goizueta Business School in 2014.

  • Better Buy: AbbVie Inc. vs. Johnson & Johnson
    Motley Fool5 days ago

    Better Buy: AbbVie Inc. vs. Johnson & Johnson

    Which stock wins in a match-up between these two big pharma companies?

  • InvestorPlace6 days ago

    The Philosophy of Dividend Aristocrat Stocks

    One popular form of dividend investing involves a group of stocks called dividend aristocrats. Standards of what makes up a dividend aristocrat vary. Of the thousands of stocks that trade on American exchanges, only 53 stocks currently hold dividend aristocrat status.

  • TheStreet.com6 days ago

    Buy Johnson & Johnson, Now Poised to Rally

    In this daily bar chart of JNJ, below, we can see that JNJ has been testing the declining 200-day moving average line. The daily On-Balance-Volume (OBV) line has been going up since early June and it is close to making a new high above the April peak. A rising OBV line is a sign that buyers of a stock are being more aggressive.

  • Shire, Shionogi File NDA for Intuniv for Adults in Japan
    Zacks6 days ago

    Shire, Shionogi File NDA for Intuniv for Adults in Japan

    Shire's (SHPG) Japanese partner Shionogi & Co., Ltd submits a new drug application for Intuniv in Japan for the treatment of attention deficit hyperactivity disorder (ADHD) in adults.

  • 3 Biotech Stocks With Major Catalysts Incoming
    Motley Fool6 days ago

    3 Biotech Stocks With Major Catalysts Incoming

    Clinical trial results and an FDA approval decision will move these three stocks in the weeks ahead.

  • Rare Genetic Mutation May Help Drugmakers Battle Obesity
    Bloomberg Video4 days ago

    Rare Genetic Mutation May Help Drugmakers Battle Obesity

    Aug.15 -- People who have a rare genetic mutation called essential fructosuria lack the primary enzyme needed to metabolize fructose, a natural sugar found in honey, fruits and vegetables. No ill consequences have been linked to the defect, save for an aversion to sweets, and it appears to have a significant benefit: Those who have it seem to be at little risk of obesity, type 2 diabetes or serious liver ailments. Bloomberg's Timothy Annett has more on "What'd You Miss?"

  • Jury orders Monsanto to pay $289 million in Roundup cance...
    CNBC Videos6 days ago

    Jury orders Monsanto to pay $289 million in Roundup cance...

    CNBC's Aditi Roy reports on the lawsuit against Monsanto over its allegedly carcinogenic herbicide, Roundup.